EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
- Posted on June 23, 2026
- By Bing News
- 0 Views
- 1 min read
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Sanofi SNY announced that the European Commission has approved its Bruton's tyrosine kinase (BTK) inhibitor, Cenrifki (tolebrutinib), for treating secondary progressive multiple sclerosis (SPMS) in adult patients who have not experienced relapses in the past two years. Following the nod, Cenrifki became the first disability-targeting medicine to be approved for SPMS without relapses in the EU. Sanofi will launch Cenrifki in Germany later this...
